Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.56 - $15.21 $410,112 - $1.75 Million
115,200 Added 313.9%
151,900 $2.31 Million
Q2 2024

Aug 14, 2024

BUY
$4.63 - $7.09 $63,894 - $97,842
13,800 Added 60.26%
36,700 $175,000
Q1 2024

May 15, 2024

BUY
$3.61 - $6.88 $30,685 - $58,480
8,500 Added 59.03%
22,900 $155,000
Q4 2023

Feb 14, 2024

SELL
$2.71 - $5.08 $26,287 - $49,276
-9,700 Reduced 40.25%
14,400 $70,000
Q3 2023

Nov 14, 2023

BUY
$3.42 - $7.85 $58,482 - $134,235
17,100 Added 244.29%
24,100 $82,000
Q2 2023

Aug 14, 2023

SELL
$3.76 - $5.05 $122,576 - $164,630
-32,600 Reduced 82.32%
7,000 $33,000
Q1 2023

May 15, 2023

SELL
$3.78 - $5.03 $390,096 - $519,096
-103,200 Reduced 72.27%
39,600 $167,000
Q4 2022

Feb 14, 2023

SELL
$3.36 - $6.55 $1,680 - $3,275
-500 Reduced 0.35%
142,800 $551,000
Q3 2022

Nov 14, 2022

BUY
$3.61 - $6.08 $308,655 - $519,840
85,500 Added 147.92%
143,300 $860,000

Others Institutions Holding CAPR

About CAPRICOR THERAPEUTICS, INC.


  • Ticker CAPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 24,346,200
  • Market Cap $465M
  • Description
  • Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for th...
More about CAPR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.